

Peer Review File

Article information: <https://dx.doi.org/10.21037/tcr-24-1048>

Reviewer A

Comment 1: Please attempt to reveal the biological and clinical relevance of lncRNAs in the occurrence and metastasis of ESCC tumors based on the content of this study.

Reply 1: Thank you very much for your valuable suggestion. We have revealed the biological and clinical relevance of lncRNAs in the occurrence and metastasis of ESCC tumors

Changes in the text: Line 54-85 have been highlighted in red.

Comment 2: How to consider lncRNAs as metastasis-mediated effectors? What are the main aspects included? Suggest adding relevant content.

Reply 2: Thanks for the constructive suggestions. The detailed revisions are given as follows for your reference.

Changes in the text: Line 137-159 have been highlighted in red.

Comment 3: Suggest increasing the impact of lncRNAs on the pathogenesis and potential drug development of ESCC.

Reply 3: Thanks for the helpful comments. We have increased the impact of lncRNAs on the pathogenesis and potential drug development of ESCC. Detailed corrections are given below for your reference.

Changes in the text: Line 178-197 have been highlighted in red.

Comment 4: Suggest adding descriptions of reconstitution therapy and inhibition of the corresponding long non-coding RNAs with small interfering RNAs and antisense oligonucleotides.

Reply 4: Thanks for your valuable suggestion. The descriptions of reconstitution therapy and inhibition of the corresponding long non-coding RNAs with small interfering RNAs and antisense oligonucleotides have been added in the revision.

Changes in the text: Line 311-328 have been highlighted in red.

Comment 5: Please summarize the current status of lncRNAs in augmenting resistance/sensitivity in ESCC against radiotherapy.

Reply 5: Thanks for the suggestion. The current status of lncRNAs in augmenting resistance/sensitivity in ESCC against radiotherapy has been rewritten.

Changes in the text: Line 329-346 have been highlighted in red.

Comment 6: What are the problems and challenges that need to be overcome in the clinical application lncRNA? It is recommended to add relevant content.

Reply 6: Thanks for your valuable suggestion. The relevant content have been added in the revision.

Changes in the text: Line 348-380 have been highlighted in red.

Reviewer B

Comment 1: For a Narrative Review, the Abstract should be structured with Background and Objective, Methods, Key Content and Findings, and Conclusions. Please modify.

Reply: Thanks for the suggestion. Changes in the text: Line 35-52 have been highlighted in red.

Comment 2: Please check through your article to make sure all the abbreviated terms have been defined when they first appear in the Abstract and the main text. “TGF-β” “TNM” “miRNAs” “MAPK” “JAK/STAT” “mRNAs” in the main text for example.

Reply: Thanks for your valuable suggestion. All proper nouns appearing for the first time in the text have been defined.

Comment 3: In the main text, the citations should be in regular round brackets with a space before. Please check through and revise.

[e.g. Their roles extend across a spectrum of cellular processes, prominently influencing gene expression, cell cycle regulation, and apoptosis, thereby implicating them in the pathogenesis of various diseases, including cancer (1,2).]

Reply: Thank you very much for your valuable suggestion. All references in the text have been changed to normal round brackets.

Comment 4: Please check if any reference should be added since you mention “studies”.

-Studies indicate that LINC00624, an immunosuppressive LncRNAs in cancer, has significant therapeutic potential when targeted by ASOs in tumors expressing high levels of LINC00624¹²³.

Reply: Thanks for the constructive suggestions. Bibliography has been added after ‘Research’. Changes in the text: Line 332 have been highlighted in red.

Comment 5: Reference 6 and 38, 28 and 112, 104 and 116 are duplicate. Please check.

Reply: Thanks for the helpful comments. Duplicate references in the text have been corrected.

Comment 6: Figures and Tables

-All Figures are not clear enough. Please provide them in higher resolution.

-The citation of Figures 2-9 is missing in the text.

-Please indicate the meaning of the symbol in Figures 2-9.



Reply: Thanks for your valuable suggestion.

-Please check Figure 2. It should be “PI3K”?



Reply: Thanks for your valuable suggestion. Yes, changes have been made.

-All abbreviations in figures/tables and legends should be explained. “LncRNA” “ESCC” “EAC” in Figure 1, and “LncRNAs” “ESCC” “EAC” in Table 1 for example. Please check all abbreviations and provide the full names in the corresponding legends.

Reply: Thanks for your valuable suggestion. All abbreviations in figures/tables and legends have been explained

-Please cite Table 1 in the Methods section.

Reply: Thanks for your valuable suggestion. Table 1 has been cited in the Methods section

-Table 2: The DOI is missing here?

LINC012 96	ESC C	Tissue	U	stage and lymph node metastasi	proliferati on migration invasion	poor prog nosi s	3041 6853	
---------------	----------	--------	---	---	--	---------------------------	--------------	--

Reply: Thanks for your valuable suggestion. Missing DOIs have been added .

-In all tables, please uppercase the first letter of each column.

Reply: Thanks for your valuable suggestion. In all tables, the first letter of each column has been capitalised.

-Please indicate the meaning of “U” in Table 2, and “D” in Table 3.

Reply: Thanks for your valuable suggestion. ‘U’ in Table 2 represents high expression and “D” in Table 3 represents low expression. Indicated in the text.